Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex - Authors' reply
- PMID: 37442148
- DOI: 10.1016/S1473-3099(23)00423-1
Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex - Authors' reply
Conflict of interest statement
KSK was a member of the Data Safety Monitoring Committee for the ATTACK trial; has received consulting fees from Entasis Therapeutics, Merck, Shionogi, Qpex Biopharma, GlaxoSmithKline, MicuRx Pharmaceuticals, AbbVie, Johnson & Johnson, Venatorx Pharmaceuticals, and Allecra Therapeutics; and owns stock options in Merck. At the time of the ATTACK trial, SMM, JPO’D, and DA were employees of Entasis Therapeutics. SMM, JPO’D, and DA are currently employees of Innoviva Specialty Therapeutics, an affiliate of Entasis Therapeutics.
Comment on
-
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. Lancet Infect Dis. 2023. PMID: 37182534 Clinical Trial.
-
Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex.Lancet Infect Dis. 2023 Aug;23(8):e274. doi: 10.1016/S1473-3099(23)00422-X. Epub 2023 Jul 10. Lancet Infect Dis. 2023. PMID: 37442147 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources